CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...

We appreciate the letter by Dombi et al 1 discussing the pivotal, phase IIb, ReNeu trial (ClinicalTrials.gov identifier: NCT03962543), 2 which notes a high proportion of mirdametinib-treated patients ...

Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas. If you have the appropriate software installed, you can download article citation data to the ...

Transcript How does the recent approval of mirdametinib change the treatment landscape for NF1-associated plexiform neurofibromas, particularly for children?

The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not ...

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable to complete surgical resection are indicated in the approval.

Plexiform neurofibromas (PN) are tumors that grow in an infiltrative pattern along the peripheral nerve sheath, resulting in pain and functional impairment in patients with NF1.

Multiple tigers in Ratapani Tiger Reserve are affected by fibroma, raising concerns among wildlife conservationists. Despite reports since June 2024, ...

Data from the Phase III KOMET trial demonstrated that Koselugo (selumetinib; Alexion, AstraZeneca Rare Disease, and Merck), an oral MEK inhibitor targeting neurofibromatosis type 1 (NF1), demonstrated ...

Plexiform neurofibromas are tumors that grow along nerves. That’s how they get their name: "neuro" means nerves, and "fibroma" is a type of tumor. These growths have nerve tissue and many ...

The FDA has granted Priority Review to SpringWorks Therapeutics’ New Drug Application (NDA) for mirdametinib, an investigational MEK inhibitor for the treatment of neurofibromatosis type 1-associated ...

The progression of neurofibromatosis type 1-associated plexiform neurofibromas can vary from person to person and from tumor to tumor.